Страна: Канада
Език: английски
Източник: Health Canada
NAPROXEN
APOTEX INC
M01AE02
NAPROXEN
250MG
TABLET
NAPROXEN 250MG
ORAL
100/1000
Prescription
OTHER NONSTEROIDAL ANTIIMFLAMMATORY AGENTS
Active ingredient group (AIG) number: 0109634001; AHFS:
MARKETED
1982-12-31
_APO-NAPROXEN, APO-NAPROXEN SR, APO-NAPROXEN EC (Naproxen Tablets) _ _Page 1 of 53_ PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION PR APO-NAPROXEN Naproxen Tablets Tablets, 125 mg, 250 mg, 375 mg and 500 mg, Oral USP PR APO-NAPROXEN SR Naproxen Sustained-Release Tablets Sustained-Release Tablets, 750 mg, Oral Apotex Standard PR APO-NAPROXEN EC Naproxen Enteric-Coated Tablets Enteric-Coated Tablets, 250 mg, 375 mg and 500 mg, Oral Apotex Standard ATC Code: M01AE02 Non-Steroidal Anti-Inflammatory Drug (NSAID) APOTEX INC. 150 Signet Drive Toronto, Ontario M9L 1T9 Date of Initial Authorization: December 31, 1982 Date of Revision July 26, 2023 _ _ Submission Control Number: 272842 _APO-NAPROXEN, APO-NAPROXEN SR, APO-NAPROXEN EC (Naproxen Tablets) _ _Page 2 of 53_ RECENT MAJOR LABEL CHANGES 2 CONTRAINDICATIONS 07/2023 3 SERIOUS WARNING AND PRECAUTIONS BOX 07/2023 7 WARNINGS AND PRECAUTIONS 07/2023 7 WARNINGS AND PRECAUTIONS, 7.1.1 Pregnant Women 07/2023 TABLE OF CONTENTS SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF AUTHORIZATION ARE NOT LISTED. RECENT MAJOR LABEL CHANGES ............................................................................................ 2 TABLE OF CONTENTS ............................................................................................................. 2 PART I: HEALTH PROFESSIONAL INFORMATION ..................................................................... 4 1 INDICATIONS ................................................................................................................. 4 1.1 Pediatrics ...................................................................................................................... 4 1.2 Geriatrics ...................................................................................................................... 4 2 CONTRAINDICATIONS ..................................................................................................... 5 3 SERIOUS WARNINGS AND PRECAUTIONS BOX .................................. Прочетете целия документ